Compare FTEL & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTEL | ALZN |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 9.0M |
| IPO Year | 2023 | 2021 |
| Metric | FTEL | ALZN |
|---|---|---|
| Price | $0.88 | $2.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $42.00 |
| AVG Volume (30 Days) | ★ 11.1M | 98.5K |
| Earning Date | 11-17-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,200,138.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.42 | N/A |
| 52 Week Low | $0.62 | $1.88 |
| 52 Week High | $792.00 | $12.06 |
| Indicator | FTEL | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 36.31 | 49.49 |
| Support Level | $0.80 | $2.03 |
| Resistance Level | $2.00 | $2.35 |
| Average True Range (ATR) | 0.21 | 0.18 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 17.31 | 51.47 |
Fitell Corp engages in primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiaries. It operates in two segments: online fitness equipment distribution and licensing business to service the large and growing boutique fitness sector of the broader health and fitness club industry. The majority fitness equipment business is conducted in Australia via its own e-commerce platform and, through third-party sites. Licensing service offers a turnkey solution for personal training studios and commercial gym chains. The company earns maximum of revenue for retail.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.